Evidence map›Paper›PMID 40557198›Full record

ArticleProceedings (Baylor University. Medical Center)2025

Evaluating the efficacy and safety of survodutide for obesity: a systematic review and meta-analysis of randomized controlled trials.

Abdelaziz A Awad, Alaa Abdrabou Abouelmagd, Fatma Mohammed, Abdelrahman M Elettreby, Mohamed Mahmoud Marey, Mohamed A Aldemerdash, Samar M Soliman, Mohamed Mohamed Belal, Hazem Abosheaishaa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings (Baylor University. Medical Center), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Survodutide: a novel peptide for treatment of obesity and metabolic diseases.Proceedings (Baylor University. Medical Center) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Abdelaziz A AwadFaculty of Medicine, Al-Azhar University, Cairo, Egypt.ORCID https://orcid.org/0009-0005-7922-6436
Alaa Abdrabou AbouelmagdFaculty of Medicine, South Valley University, Qena, Egypt.
Fatma MohammedFaculty of Medicine, Aswan University, Aswan, Egypt.
Abdelrahman M ElettrebyFaculty of Medicine, Mansoura University, Mansoura, Egypt.
Mohamed Mahmoud MareyFaculty of Medicine, Alexandria University, Alexandria, Egypt.
Mohamed A AldemerdashFaculty of Medicine, Sohag University, Egypt.
Samar M SolimanFaculty of Medicine, Alexandria University, Alexandria, Egypt.
Mohamed Mohamed BelalFaculty of Medicine, Alexandria University, Alexandria, Egypt.
Hazem AbosheaishaaIcahn School of Medicine at Mount Sinai, New York, New York, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Glucagon-like peptide-1 (GLP-1) agonists have established their efficacy and safety in the treatment of obesity. In this study, we aimed to assess the efficacy and safety of survodutide, a new GLP-1 agonist. Methods: We searched PubMed, Web of Science, Scopus, and Cochrane Library databases until May 2024 for randomized controlled trials using survodutide obesity treatment. Continuous data were pooled as standardized mean difference (SMD), while dichotomous data were pooled as risk ratios (RR) with 95% confidence intervals. Results: There was a significant relative body weight reduction in the survodutide group (SMD: -1.5; 95% CI: -2.05 to -0.95; Conclusion: Survodutide effectively reduced relative body weight, absolute body weight, and hemoglobin A1c (

Indexed as

Meta-analysisobesityreviewsurvodutide

Identifiers

PMID40557198
PMCPMC12184113

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.